首页> 外文会议>SPIE Conference on Biophotonics and Immune Responses >Novel liposomal combination treatments using dual genes knockdown in oral cancer treatment
【24h】

Novel liposomal combination treatments using dual genes knockdown in oral cancer treatment

机译:新型脂质体组合治疗在口腔癌治疗中使用双基因敲低

获取原文

摘要

Small interfering RNA (siRNA) can be used to treat tumor because it can effectively knockdown target oncoprotein expression and it leads to cancer cell death and apoptosis. Hypoxia-inducible factors-1 (HIF-1) is a transcription factor gene. Its high expression of tumor hypoxia cells, activation of transcription factor HIF-lα and angiogenesis found in most cancerous tissues. HIF-lα protein in cancer cells are critical to cell survival, tumor growth and proliferation. Epidermal growth factor receptor (EGFR) gene is another common head and neck oncogene. The dual self-designed siRNA sequences were encapsulated in the lipid-calcium-phosphate (LCP) and targeted to sigma receptors on the surface of cancer cells via binding to amino ethyl anisamide (AEAA). We used human oral cancer cells to establish the xenograft animal model to study the combination therapy for therapeutic results.
机译:小干扰RNA(siRNA)可用于治疗肿瘤,因为它可以有效地敲低靶癌蛋白表达并导致癌细胞死亡和凋亡。缺氧诱导因子-1(HIF-1)是转录因子基因。其高表达肿瘤缺氧细胞,在大多数癌组织中发现转录因子HIF-1α和血管生成。癌细胞中HIF-Lα蛋白对细胞存活,肿瘤生长和增殖至关重要。表皮生长因子受体(EGFR)基因是另一种常见的头部和颈部癌基因。双自行设计的siRNA序列被包封在脂质 - 磷酸钙(LCP)中,并通过与氨基乙基氨基酰胺(AEAA)结合,靶向癌细胞表面上的Sigma受体。我们使用人口腔癌细胞来建立异种移植动物模型,以研究治疗结果的联合治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号